MRUS (Merus N.V.) Stock Market Reviews

crown

search

Read and share opinions on MRUS (Merus N.V.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

MRUS

Merus N.V.

clarify Biotechnology

bookmark Healthcare

public Netherlands

Sell Neutral Buy

Latest News

Merus (MRUS): Assessing Valuation After Recent 38% Stock Gain
Oct 27, 2025
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Oct 24, 2025
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Oct 21, 2025
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 14, 2025
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 13, 2025
Merus (MRUS): Assessing Valuation After Rapid Share Price Gains
Oct 12, 2025
Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential
Oct 2, 2025
Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium
Sep 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
Sep 30, 2025
Genmab's $8 Billion Bid Represents 'Good Deal' for Merus' Petosemtamab, Truist Says
Sep 29, 2025
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Sep 29, 2025

Reviews